Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Personalis Total Change in Assets/Liabilities 2018-2024 | PSNL

Personalis total change in assets/liabilities from 2018 to 2024. Total change in assets/liabilities can be defined as the sum of all line items in the Asset/Liability section of the Cash Flows Statement
  
Personalis Annual Total Change in Assets/Liabilities
(Millions of US $)
2024 $-3
2023 $13
2022 $11
2021 $-31
2020 $-17
2019 $-7
2018 $15
2017 $21
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.323B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.010B 6.96
Dr Reddy's Laboratories (RDY) India $11.261B 21.48
BridgeBio Pharma (BBIO) United States $6.894B 0.00
Bausch Health Cos (BHC) Canada $2.638B 1.91
Supernus Pharmaceuticals (SUPN) United States $1.805B 24.57
Amphastar Pharmaceuticals (AMPH) United States $1.553B 9.33
Taysha Gene Therapies (TSHA) United States $0.338B 23.57
Assembly Biosciences (ASMB) United States $0.080B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00